All posts by medical

When the Facts Change, We Change Our Minds (Anatomy of a Sale) – Yahoo Finance

Even before the coronavirus, we were not big fans of the airlines business. Planes are expensive. Airlines have to pay for them whether they are fully occupied during normal economic times or when they are half-loaded during recessions. Their other big cost is fuel - airlines have little control over it. If they hedge the oil price and it goes up, they are heroes. If they hedge oil and it declines, their unhedged competition will have an economic advantage. It is very difficult to develop competitive advantage; customers usually have very little loyalty and price is the deciding factor for most buying decisions.

Warren Buffett (Trades, Portfolio) invested in the airlines industry in the '80s, lost money, and swore he'd never invest in it again. However, after the Great Financial Crisis the industry went through significant consolidation by mergers and attrition, leaving four carriers controlling the bulk of the market. Fewer competitors made competition more rational and turned these airlines into much better businesses. So Buffett changed his mind and bought a 10% stake in all four of the largest U.S. airlines. For a few years it seemed that he was finally right about the airlines.

Airlines were never our cup of tea. The high fixed-cost structure of the industry and its past history of going bankrupt every other recession made our EQ when it comes to airlines very low. When Buffett bought them, for some value investors, the airlines had been blessed by the high priest. We are agnostic (growing up in Soviet Russia has its rare benefits) and have to own our decisions, so we passed on the airlines without spending much time thinking about them.

Typically, when you go into recession you can look at the rear-view mirror earnings for a cyclical company and that becomes your goalpost for future earnings power within a year or two, max. We don't know how long it will take until we'll again see the 2019 earnings power of airlines and the travel industry in general. Here is what we know. Though it is hard to imagine this today, the fear of COVID-19 will eventually go away, either because there is a vaccine or a cure, or because the virus is gone, or because we will simply adapt to its existence.

But even in absence of a vaccine or cure, we'll change our behavior, and that will happen slowly on the margin. After being locked up for a few months, not seeing friends and relatives except on Zoom or Facetime, we'll timidly visit their houses and sit six feet apart on their porches. (My family did this on Mother's Day.) Then we'll invite very close friends - the ones who stuck religiously to social distancing- to our homes for dinner. Then we might chance visiting a restaurant with outdoor seating. Then, on a rainy day, we'll go inside the restaurant and find that it now has huge spacing between the tables. We'll make a lot of small incremental decisions; each will be a tiny compromise that will nudge us out of our fear.

Of course, each time we read about serious virus flareups, we'll take one step back.

Flying is at one extreme in the spectrum of social distancing. It requires finding your way through airports packed with people and then getting on a plane that, even after the middle seats are removed will still have a higher density than a packed bar on Friday night in Manhattan. Thus flying will require a great many little, incremental, marginal decisions before we overcome the fear of boarding a plane.

Vaccine availability would instantly vanquish fear, and our behavior would come back to normal. Well, almost. There will be scar tissue on the economy - trillions in government debt and persistently high unemployment - that will take time to clear up. People are not flying today because we are in lockdown; they'll be flying less than they used to after lockdown is over because they are still afraid; and after their fear is gone they'll still be flying less because they cannot afford the flights.

We imagine that when Buffett bought airlines in 2015, he thought the worst case would be a significant recession where plane occupancy would fall from the usual 80-90% to 50-60% (according to the FT, only four airlines out of a few hundred are profitable at 62% occupancy). His thinking was that the airlines would lose some money for a few quarters, but the recession would be anything but an existential crisis for them. Recessions last months and expansion years, and he thought he had bought them cheap on full-cycle (both recession and expansion) earnings.

Story continues

Despite being the Oracle of Omaha, he did not foresee that one day we might have a different type of recession where 95% of the planes would be grounded, not because people couldn't afford to buy a tickets but because they would be required to stay home by their governments, or would be afraid that close proximity to others would make them sick or even kill them.

Very few businesses can survive when 95% of their revenue goes away for an extended period of time. Even fewer can survive when they have a large fixed-asset base that needs to be paid for whether they are using it or not.

The sad reality is that unless airlines raise new capital, they will go bankrupt. This capital, though it might save them, will reduce the value of their businesses. Equity issuances, especially at today's depressed stock prices, would permanently dilute shareholders, as future earnings will be shared with a much-increased shareholder base.

If the airlines issue debt, it will not be cheap capital, either, and will burden these companies, which already have a lot of fixed costs, with another cost - significant interest payments that will substantially reduce their future earnings power. The longer the fear of the virus lingers on, the more money these companies will lose and the greater the damage that will be done to their balance sheets and thus their future earnings power.

In our thinking about the virus we have three timelines, or eras: BC - before coronavirus, DC - during coronavirus (now), and AC - after coronavirus (the virus is completely gone, or there is a vaccine or effective treatment. The longer the DC era lasts the more impact it has on the AC era. The DC era comes with high unemployment and enormous government spending - larger deficits and an ever-growing debt pile that is no longer counted in billions but in trillions.

The future of the airlines is path-dependent, and they have little control over that path; it is controlled by the virus (or the fear of the virus).

We don't own airlines, so why am I spending so much time talking about them? There are several reasons. First, because they are companies that are antithetical to our portfolio philosophy. Charlie Munger (Trades, Portfolio) says, "Tell me where I am going to die so I won't go there." So it's worth having a clear picture of the types of businesses you don't want to own.

Second, we wanted to point out Buffett's ability to change his mind. Interestingly, Buffett, who was already the largest shareholder of U.S. airlines, bought more airline stocks a few weeks before he sold them. We did something similar this quarter, too: We increased our position in Melrose Industries, just to sell the full position two weeks later. (More about Melrose to follow).

Third, like Buffett, we were playing traditional chess, not realizing that the game had changed to Fischer random chess. We were following the normal recession handbook (mental models) but then realized that this is anything but a normal recession. We have to be incredibly careful about using our past mental models today; they were built in a very different environment. Today, past experience is not useless, but if relied on blindly it can be dangerous. Some things will play out in the future as they have in the past, but many won't.

We needed to start using a first-principles approach - a concept we shamelessly borrowed from physics. We took out a blank piece of paper, assumed we knew nothing, and instead of continuing to think by analogy, started questioning every assumption we make in our analysis.

Our decision to sell Melrose Industries (LSE:MRO) is very similar to Buffett's sale of the airlines. We sold Melrose before the Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) annual meeting. It was a difficult decision, not because we cemented a loss but because we parted with a business we really liked, that was run by good management, and that was significantly undervalued when we bought it.

When we were buying Melrose we stress-tested it for a severe recession; however, the decline that Melrose is probably experiencing today did not occur to us in our wildest imagination. Melrose is a very strong player in two industries that have been impacted tremendously: the airlines space (it makes parts that go into planes and engines) and car parts (it is one of the largest makers of transmissions for cars). We talked to the company. It has credit lines and cash to give it immediate liquidity, but we are not sure if it will be enough.

We had applied the traditional recession mental model to our analysis, and we were wrong. Given the world we are looking at now, we should have sold it sooner.

Buying new planes is the last thing on airlines' minds today. Also, only 20% of Melrose's business comes from replacement parts. Melrose's auto parts business (ironically, the business we worried about the most when we bought the stock) may be okay; it may even generate some profit; but we are not sure it will be able to sustain the company. We simply don't know what the losses are going to be in the airlines space and for how long. We have a tremendous respect for the Melrose management team - they're a big reason why we bought the stock - but at this point the problem that Melrose is facing is bigger than them.

If you look carefully through your portfolio, you'll see that we've positioned it to the opposite side of spectrum from the airlines. Most of our holdings are concentrated in four industries: defense, healthcare, tobacco (where we are permitted by clients), and telecommunications. These industries have one thing in common: They will not be structurally impacted by the virus.

Consumption of goods and services in the four industries is completely insensitive to the virus. These companies all have very stable cash flows and pricing power - in the event of deflation they'll maintain their prices, while during inflation they'll raise them.

And one more thing...

I am not a journalist or reporter; I am an investor who thinks through writing. This and other investment articles are just my thinking at the point they were written. However, investment research is not static, it is fluid. New information comes our way and we continue to do research, which may lead us to tweak and modify assumptions and thus to change our minds.

We are long-term investors and often hold stocks for years, but as luck may or may not have it, by the time you read this article we may have already sold the stock. I may or may not write about this company ever again. Think of this and other articles as learning and thinking frameworks. But they are not investment recommendations. The bottom line is this. If this article piques your interest in the company I've mentioned, great. This should be the beginning, not the end, of your research.

Vitaliy Katsenelson, CFA

Student of Life

I am the CEO at IMA, which is anything but your average investment firm. (Why? Get our company brochure in your inbox here, or simply visit our website.)

In a brief moment of senility, Forbes magazine called me "the new Benjamin Graham."

I've written two books on investing, which were published by John Wiley & Sons and have been translated into eight languages. (I'm working on a third - you can read a chapter from it, titled "The 6 Commandments of Value Investing" here.)

And if you prefer listening, audio versions of my articles are published weekly at investor.fm.

This article first appeared on GuruFocus.

Read more:
When the Facts Change, We Change Our Minds (Anatomy of a Sale) - Yahoo Finance

Greys Anatomy Season 17: Greys Anatomy : Official Journal On The Start ? – Auto Freak

Season 17 of Greys Anatomy is in complete preparation. Everybody wonders what will happen to Oj following the passing of Alex.

In a month or two, fans of Greys Anatomy will have the ability to observe the year 17. But we are asked whatll happen to Oj following the departure of Alex. Beware; the report contains spoilers.

- Advertisement -

Fans of Greys Anatomy havent been able to see all of the episodes of season 16. In reality, because of the Covid-19, the series runners havent released the previous four episodes of this year.

That the fans have frustrated since the last episode gave a play. Nonetheless, the season has not been without turns and twists, and fans have had to confront the departure of a personality flagship.

In fact, Alex played with Justin Chambers has selected to depart Seattle in order to help his unwell mom. The latter wanted to become present for his family, and hes left behind him, his wife.

It will not seem like Alex when we know that he loves Jo, and they had just gotten married. As well, the fans are disappointed, and everybody is wondering what will happen to Jo from the year 17 of Greys Anatomy.

Jo has created a big depression, and she recovered just out of his trauma from the sequence. Therefore, the departure of Alex could well mark the conclusion of the narrative of the physician. This last one may choose to leave for Greys Anatomy.

Chris Carmack that plays Lincoln, ensures that the character of Jo is strong. Thus, according to him, the woman Karev should recuperate. I do not believe that you can get rid of it easily; shes really tough skin. And she has a great deal to give to the planet and to his patients at Grey Sloan, he explained.

Hence, Oj should be present in Greys Anatomys season 17. Shell be able to rely upon the existence of his family to create a cross on his history with Alex. Additionally, it will be a little nearer to Lincoln.

In fact, Jo is very familiar with Lincoln, and they wish to be accomplices. One may even believe that they may end up going out together from the new season. But until now, Lincoln is in a relationship with Amelia, and they come just to get a child

- Advertisement -

Read the original:
Greys Anatomy Season 17: Greys Anatomy : Official Journal On The Start ? - Auto Freak

Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries),…

New York, July 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" - https://www.reportlinker.com/p05930381/?utm_source=GNW

Product Type:Kits, Consumables, and Services Sample Type: Tumor Tissue, Blood, Saliva, Bone Marrow Technology: Next Generation Sequencing, Polymerase Chain Reaction,Immunohistochemistry, In-situ Hybridization, Microarray Techniques Oncology Genetic Testing: Breast, Colorectal,Prostate, Lung, Melanoma Cardiology Genetic Testing: Cardiomyopathy,Aortopathy, Arrythmia Neurology Genetic Testing: Epilepsy, Neurodegenerative Disorders, Neuromuscular Disorders Other Genetic Testing: Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Application Area: Academia and Research Centers, Clinical Diagnostics, Drug Discovery, Monitoring and Screening

Regional Segmentation North America U.S., Canada Europe Germany, France, Italy, U.K., Spain, Russia, Netherlands Asia-Pacific Japan, China, India, Australia, Singapore Latin America Brazil, Mexico Rest-of-the-World Kingdom of Saudi Arabia (K.S.A.), U.A.E., Palestine, Algeria

Cross Segmentation North America Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Europe Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Asia-Pacific - Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Latin America Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Rest-of-the-World Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing

Growth Drivers Rising Prevalence of Genetic Disorders Increasing Prevalence of Various Types of Cancer, Globally Increasing Research Funding in the Field of Genomics

Market Challenges Expensive Sequencing Procedures and Their Applications in Medical Treatments High Capital Requirement Hampering the Expansion of Global Reach Stringent Regulatory Standards

Market Opportunities Technological Advancements for Exome Sequencing Rise of Direct-to-Consumer (DTC) Testing Services Massive Scope for Adoption of NGS-Based in Emerging Nations

Key Companies ProfiledAgilent Technologies, Inc., Ambry Genetics, Beijing Genomics Institute (BGI), CENTOGENE AG, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Inc. Illumina, Inc. , Laboratory Corporation of America Holdings, Myriad Genetics, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.

Key Questions Answered in this Report: What are the possible long-term and short-term impacts of hereditary genetic testing on the human health continuum? What are the major market drivers, challenges, and opportunities in the hereditary genetic testing? What are the key development strategies which are being implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in the developed and developing regions for the global hereditary genetic testing market? How are service-based companies impacting the growth of the global hereditary genetic testing industry and further shaping up future trends? How each segment of the market is expected to grow during the forecast period from 2020 to 2030? Who are the leading players with significant offerings to the global hereditary genetic testing market? What is the expected market dominance for each of these leading players? Which companies are anticipated to be highly disruptive in the future, and why? What are the needs that are yet to be met by the global hereditary genetic testing market with respect to the application area? What are the dynamics of various application areas and countries are impacting the global hereditary genetic testing market? What are the new market opportunities of various technologies influencing the growth of the global hereditary genetic testing market?

Market OverviewThe hereditary genetic testing has grown significantly since the technology was first commercialized, but it is important to quantify that growth and describe future trends.The genome testing industry is proliferating, and its growth is expected to continue at its torrid pace.

However, there are significant challenges that may dampen future growth if not addressed.

Our healthcare experts have found hereditary genetic testing to be one of the most rapidly evolving technologies, and the global market for hereditary genetic testing is predicted to grow at a CAGR of 13.59% over the forecast period of 2020-2030.

The unmet clinical needs for better tools to predict, diagnose, treat, and monitor disease are acting as significant factors driving the growth of sequencing industry. Other factors driving the growth include the increased understanding of the molecular basis of disease, patient demand, industry investment, and regulations that allow marketing of tests without FDA approval.

Despite rapid advanced sequencing industry growth, there are several key issues that are needed to be addressed to facilitate future growth.The relatively high total costs of delivering sequencing test results compared with other technology platforms, and limited coverage by payers, are the key challenges to the growth of this industry.

Whole genome and exome sequencing remain relatively costly requiring initial equipment investment, specialized workforce requirements, and time-intensive variant interpretation.

Within the research report, the market is segmented on the basis of oncology genetic testing, cardiology genetic testing, neurology genetic testing, product, sample, application area, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive LandscapeThe exponential rise in the application of next generation sequencing on the global level has created a buzz among companies to invest in the products and services of whole genome and exome sequencing. Due to the diverse product portfolio and intense market penetration, whole genome and exome has been a pioneer in this field and been a significant competitor in this market.

On the basis of region, North America holds the largest share, due to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Latin America and the Asia-Pacific region are anticipated to grow at the fastest CAGR during the forecast period.

Countries Covered North America U.S. Canada Europe Germany France Italy U.K. Spain Russia Netherlands Rest-of-Europe Asia-Pacific China Japan India Australia Singapore Rest-of-APAC Latin America Brazil Mexico Rest-of-Latin America Rest-of-the-World (RoW)Read the full report: https://www.reportlinker.com/p05930381/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the original here:
Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries),...

ACMG’s Genetics in Medicine Journal Receives Impact Factor of 8.904 for 2019–Journal is Ranked 13th of 177 Journals in Genetics & Heredity -…

BETHESDA, Md., July 8, 2020 /PRNewswire/ --The American College of Medical Genetics and Genomics (ACMG) announced today that the 2019 Journal Impact Factors, published by Clarivate Analytics in the latest edition of Journal Citation Reports, calculated an impact factor of 8.904 for ACMG's official journal, Genetics in Medicine (GIM). This is the second highest Impact Factor in the journal's history and ranks GIM 13th of 177 titles in the Genetics & Heredity category.

The Impact Factor is an objective measure of the world's leading journals, based on articles' cited references and is oft considered a measure of a journal's impact, overall successful performance and relevance to its field. The most highly cited article in GIM in 2019 was "Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing, 2016 Update (ACMG SF v2.0): A Policy Statement of the American College of Medical Genetics and Genomics."

"GIM's editors and editorial staff are delighted that our Impact Factor has increased from last year. This improvement in the Impact Factor once again demonstrates that the journal remains one of the most widely read and cited journals publishing clinically relevant research in the life sciences," said GIM's Editor-in-Chief Robert D. Steiner, MD, FAAP, FACMG."We are most thankful to the peer reviewers who put in countless hours to help maintain the outstanding quality of articles and the authors who trust us to disseminate their groundbreaking scholarly work. The Impact Factor is one of a number of metrics used to evaluate journals, and a journal should not be evaluated solely on that one metric. Genetics in Medicine'scontinued success and relevance is also reflected in our very high overall downloads and reads as well as a prominent social media presence."

ACMG CEO Maximilian Muenke, MD, FACMG said, "As the CEO of the ACMG, I am extremely proud of 'our' journal. As a physician-scientist who before joining ACMG worked in academic settings where publishing in high-impact factor journals was the goal, I am well aware of the importance of this metric. My congratulations and gratitude on increasing GIM's impact factor go to Bob Steiner, Jan Higgins, the GIM staff and the entire editorial team to make this success happen!"

Genetics in Medicineis published by Springer Nature. The journal, published since 1998, is supported by an expert board of editors representing all facets of genetic and genomic medicine, including biochemical and molecular genetics, cytogenetics, and the application of genetics and genomics to other medical specialties such as oncology, cardiology, neurology, pediatrics, ophthalmology and maternal-fetal medicine.

About the American College of Medical Genetics and Genomics (ACMG) and ACMG Foundation

Founded in 1991, the American College of Medical Genetics and Genomics (ACMG) is the only nationally recognized medical professional organization solely dedicated to improving health through the practice of medical genetics and genomics, and the only medical specialty society in the US that represents the full spectrum of medical genetics disciplines in a single organization. The ACMG is the largest membership organization specifically for medical geneticists, providing education, resources and a voice for more than 2,300 clinical and laboratory geneticists, genetic counselors and other healthcare professionals, nearly 80% of whom are board certified in the medical genetics specialties. ACMG's mission is to improve health through the clinical and laboratory practice of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and public health. Four overarching strategies guide ACMG's work: 1) to reinforce and expand ACMG's position as the leader and prominent authority in the field of medical genetics and genomics, including clinical research, while educating the medical community on the significant role that genetics and genomics will continue to play in understanding, preventing, treating and curing disease; 2) to secure and expand the professional workforce for medical genetics and genomics; 3) to advocate for the specialty; and 4) to provide best-in-class education to members and nonmembers. Genetics in Medicine, published monthly, is the official ACMG journal. ACMG's website (www.acmg.net) offers resources including policy statements, practice guidelines, educational programs and a 'Find a Genetic Service' tool. The educational and public health programs of the ACMG are dependent upon charitable gifts from corporations, foundations and individuals through the ACMG Foundation for Genetic and Genomic Medicine.

Kathy Moran, MBA[emailprotected]

SOURCE American College of Medical Genetics and Genomics

http://www.acmg.net

Continued here:
ACMG's Genetics in Medicine Journal Receives Impact Factor of 8.904 for 2019--Journal is Ranked 13th of 177 Journals in Genetics & Heredity -...

Researchers Discover Genetic Variants Linked to Type 2 Diabetes – HealthITAnalytics.com

July 08, 2020 -In the largest study of its kind, researchers discovered hundreds of novel genetic variants linked to type 2 diabetes, potentially improving care for millions living with this disease.

A team from the Perelman School of Medicine at the University of Pennsylvania and the Veterans Health Administrations (VHA) Corporal Michael J. Crescenz Veterans Affairs Medical Center (CMCVAMC) examined the genes of more than 200,000 people around the world with type 2 diabetes.

In addition to uncovering new genetic variants linked to the condition, researchers identified gene variants that vary by ethnicity, as well as variants tied to conditions related to type 2 diabetes like coronary heart disease and chronic kidney disease.

The group used data from the worlds largest biobank, the Million Veteran Program (MVP) in the VHA, as well as data from the DIAGRAM Consortium, the UK Biobank, the Penn Medicine Biobank, and Biobank Japan. Researchers analyzed a study population of 1.4 million people around the world, of whom almost 230,000 had type 2 diabetes.

The team then broke down the genetic makeup of those hundreds of thousands with type 2 diabetes and found 558 independent genetic variants that are differentially distributed between people with and without type 2 diabetes. Twenty-one of these variants were specific to European ancestry while seven were specific to African American ancestry. Of the 558 variants found, 286 had never been discovered.

Researchers set out to discover if certain genetic variants among this group of people could be linked to specific type 2 diabetes-related conditions.

Ultimately, three were linked to coronary heart disease, two to acute ischemic stroke, four to retinopathy, two to chronic kidney disease, and one to neuropathy, saidMarijana Vujkovic, PhD, a biostatistician at both the Perelman School of Medicine at the University of Pennsylvania, VHAs CMCVAMC and a co-leader for the VHAs national MVP Cardiometabolic Working Group.

Building on this research, the scientific community can assess which of the surrounding genes nearby the identified genetic variants is likely to be the causal gene that alters the risk of type-2 diabetes, and that could lead to early interventions to limit controllable risks of developing the condition.

While the researchers found many genetic variants in people with type 2 diabetes, no one variant was labeled as the worst or most dangerous.

However, just like heart disease, schizophrenia, or obesity, it is the accumulation of a large number of these variants that can add up to a considerable increase in risk, said co-senior authorBenjamin F. Voight, PhD, an associate professor of Systems Pharmacology and Translational Therapeutics at Penn, and a co-leader for the VHAs national MVP Cardiometabolic Working Group.

We hope this study can not only help find that subset of patients with substantial risk, but also to motivate new, future studies for treatments based on these findings.

Knowing more about the genetic variants linked to type 2 diabetes could help identify potential therapeutic targets for type 2 diabetes. Researchers also noted that this information could help guide treatment plans for people with the disease who may be susceptible to specific diabetes complications.

Going forward, the researchers plan to conduct a long-term examination of how genetics influence disease progression among patients with type 2 diabetes and associated metabolic disorders. The group is also leveraging the list of newly-discovered genes to investigate medication interactions.

Knowing the genetic susceptibility for diabetes complications in a patient already diagnosed with type-2 diabetes, for example through a cumulative genetic risk score, could help guide that patients care, said co-senior-authorKyong-Mi Chang, MD, a professor of Medicine at Penn, Associate Chief of Staff for Research at VHAs CMCVAMC and the Co-PI for the VHAs MVP Merit Award that supported this work.

As clinicians, we hope that these findings can ultimately be applied to improve the health outcomes for our patients including veterans.

See original here:
Researchers Discover Genetic Variants Linked to Type 2 Diabetes - HealthITAnalytics.com

Pan-Cancer Consortium Moves to Clarify and Promote Consistent Use of Common Terms for Biomarker and Germline Genetic Testing – BioSpace

WASHINGTON, July 7, 2020 /PRNewswire/ --A LUNGevity Foundation-led consortium of 41 leading patient advocacy organizations, professional societies, and industry partners has published a white paper detailing recommendations for the use of testing terminology in precision medicine for patient education throughout the cancer community. Use of consistent language will significantly improve patient awareness and understanding of potentially lifesaving testing options available for both new cancer diagnoses and progression or recurrence of disease.

Research shows that despite widespread acceptance of the importance of testing, actual testing rates lag far behind best-practice recommendations for both biomarker testing for somatic (acquired) mutations and other biomarkers, and for germline genetic testing for identifying germline (inherited) mutations (also known as variants). Analysis by The Consistent Testing Terminology Working Group (Working Group) indicates that language disparity is a primary obstacle to patient communication with providers about testing for their specific cancer type. Further, development of consistent language can increase patient understanding and communication, facilitate shared decision making, support value-based care, and assure concordance in policy development.

The Working Group is a consortium of 20 cancer patient advocacy groups representing solid tumor and hematologic malignancies, three professional societies, and 18 pharmaceutical and diagnostic companies and testing laboratories. Over the course of many years, multiple activities, led by numerous individual patient advocacy organizations and professional societies, have developed the groundwork for this effort. The Working Group has launched a multi-faceted dissemination and communications effort to ensure that its recommendations and supporting materials are widely available among all key stakeholders within the cancer ecosystem, including providers, patient advocacy organizations, guidelines agencies, payers, and policymakers.

In developing its recommendations, the Working Group, first convened in 2019 by LUNGevity Foundation, identified 33 terms related to biomarker, genetic, and genomic testing that were being used in patient education and clinical care within the different cancer communities. In many cases, multiple terms were used to describe the same test. Various testing modalities, the source of testing samples, and the multiplicity of gene mutations currently identifiable by testing were contributing factors in this often-confusing overlap.

In the final analysis, three umbrella descriptor terms emerged as recommendations from the Working Group's milestone exploration: "Biomarker testing"was selected as the preferred term for tests that identify characteristics, targetable findings, or other test results originating from malignant tissue and blood; "genetic testing for an inherited mutation" and "genetic testing for inherited cancer risk" were selected as consensus terms for tests used to identify germline (inherited) mutations.

"Far too many patients across all cancer types are still missing out on essential tests for biomarkers and inherited mutations indicating cancer risk," said Michelle Shiller, DO, AP/CP, MGP, Co-Medical Director of Genetics at Baylor Sammons Cancer Center and Staff Pathologist at Baylor University Medical Center. "With rates of biomarker testing and genetic testing for an inherited mutation at sub-optimal levels for numerous patient populations, patients are not benefiting from biomarker-directed care or not learning about their inherited cancer risk. Confusion around testing terms is a driving factor in this undertesting and ultimately has a detrimental impact on patient care."

Adds Nikki Martin, Director of Precision Medicine Initiatives at LUNGevity Foundation, "When someone is diagnosed with cancer, they're swept into a whirlwind of bewildering words and complex, pressing decisions. Our Working Group's goal is to help calm that storm of confusion with clear and consistent language that facilitates communication and medical decision-making. A unified voice and message from providers, industry, and the patient advocacy community about testing is absolutely vital to optimal cancer care."

An abstract on the Working Group's recommendations was published in May 2020 as part of the American Society of Clinical Oncology (ASCO) Annual Meeting Virtual Library.

The White Paper can be viewed in its entirety atwww.CommonCancerTestingTerminology.org.

Working Groupparticipating organizations include:

Patient Advocacy: CancerCare; Cancer Support Community;The CholangiocarcinomaFoundation;Clearity Foundation; Colorectal Cancer Alliance; Fight CRC; FORCE(Facing Our Risk of Cancer Empowered); International Cancer Advocacy Network; Leukemia & Lymphoma Society; The Life Raft Group; Lymphoma Research Foundation; Living Beyond Breast Cancer; Lung Cancer Action Network (LungCan); LUNGevity Foundation; National Lung Cancer Roundtable(American Cancer Society); PanCAN; Personalized Medicine Coalition; Prostate Cancer Foundation; Ovarian Cancer Research Alliance (OCRA); Sharsheret(The Jewish Breast & Ovarian Cancer Community);and Susan G. Komen.

Professional Societies: Association of Community Cancer Centers(ACCC);Association for Molecular Pathology(AMP); and National Society of Genetic Counselors(NSGC).

Industry Partners: Abbvie; Amgen;AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Caris Life Sciences; Eli Lilly and Company; Foundation Medicine; Genentech;GlaxoSmithKline (GSK); Novartis; Myriad Women's Health; NeoGenomics; Pfizer; Personal Genome Diagnostics (PGDx); andThermo Fisher Scientific.

About LUNGevity Foundation

LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer through research, education, policy initiatives, and support and engagement for patients, survivors, and caregivers. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the diseasewhile promoting health equity by addressing disparities throughout the care continuum. LUNGevity works tirelessly to advance research into early detection and more effective treatments, provide information and educational tools to empower patients and their caregivers, promote impactful public policy initiatives, and amplify the patient voice through research and engagement. The organization provides an active community for patients and survivorsand those who help them live better and longer lives.

Comprehensive resources include a medically vetted and patient-centric website, a toll-free HELPLine for support, the International Lung Cancer Survivorship Conference, and an easy-to-use Clinical Trial Finder, among other tools. All of these programs are to achieve our visiona world where no one dies of lung cancer. LUNGevity Foundation is proud to be a four-star Charity Navigator organization.

About Lung Cancer in the US

Please visit http://www.LUNGevity.orgto learn more.

View original content to download multimedia:http://www.prnewswire.com/news-releases/pan-cancer-consortium-moves-to-clarify-and-promote-consistent-use-of-common-terms-for-biomarker-and-germline-genetic-testing-301088874.html

SOURCE LUNGevity Foundation

Original post:
Pan-Cancer Consortium Moves to Clarify and Promote Consistent Use of Common Terms for Biomarker and Germline Genetic Testing - BioSpace

With careful adoption, soy and wheat can help maintain seniors’ muscles, says expert – Clinical Daily News – McKnight’s Long Term Care News

News > Clinical Daily News

Plant protein can help older adults maintain muscle mass, but users must adjust for any loss of animal protein when making dietary changes, say researchers.

In a new study, plant-based proteins helped to maintain the size and quality of aging muscles, wrote investigators from Kings College London. But animal proteins were more effective at helping to form muscle. A larger dose of plant protein is therefore necessary to achieve the same muscle-building response, they concluded.

Simply transitioning from an animal-based protein diet to a plant-based diet, without adjusting total protein intake, will likely be detrimental to muscle health during aging, said Professor Oliver Witard, an expert in exercise metabolism and nutrition. A more balanced and less extreme approach to changing dietary behavior, meaning eating both animal and plant-based proteins, is best, he concluded.

Plant-based diets have numerous health benefits and are becoming more popular. In fact, 39% of Americans responded that they are actively trying to eat more plant-based foods, according to a 2017 Nielsen Homescan survey.

The research was presented this week at The Physiological Societys virtual early career conference Future Physiology 2020.

Please login or register first to view this content.

LoginRegister

Next post in Clinical Daily NewsClose

Read more here:
With careful adoption, soy and wheat can help maintain seniors' muscles, says expert - Clinical Daily News - McKnight's Long Term Care News

Fluence Leads Global Research Initiative to Study Impact of Light Quality on Plant Development, Yield and Crop Quality – Financial Post

The ongoing multi-country and multi-crop initiative advances Fluences and the greater horticultural industrys understanding of the interaction between light and life

AUSTIN, Texas Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and agriculture production, has expanded its global photobiology research program, which encompasses studies on multiple vine crops, leafy greens and medical cannabis in the United States, Canada, Germany, Belgium and the Netherlands.

Tapping into a global network of trusted research institutions

Fluence leverages a network of leading research institutions and partners for its program, including Wageningen University & Research (WUR) for tomatoes; Proefstation voor de Groenteteelt (Proefstation) to study cucumbers; Harrow Research and Development Centre for peppers; The Technical University of Munichs Greenhouse Lab Centre for lettuce; Wageningen Plant Researchs Greenhouse Horticulture business unit and Compassionate Cultivation for medical cannabis.

The latest studies utilized Fluences VYPR Series top light and expanded PhysioSpec spectra offeringwhich features four spectra and market-leading efficacies up to 3.8 mol/Jin a randomized block design with triple replicates during a winter growing season. A leader in global horticultural research, WUR explored the impact of each spectrum on Merlice and Brioso tomato cultivars.

Traditionally, tomato plants are grown under high-pressure sodium lights, where only one spectrum is available to growers, said Ep Heuvelink, associate professor of horticulture and product physiology at WUR. Given the efficacy of Fluences LED solutions and the companys spectra options, its critical to understand how various tomato cultivars perform under LEDs and diversified spectra.

Featuring a 1.3-hectare greenhouse with 38 independent compartments, Proefstations facility brings more than 50 years of experience in research on the cultivation of greenhouse and field vegetables.

Light spectra have an important impact on plant and fruit quality, and weve found that LEDs provide a more optimal, precise spectrum than HPS, said Jonas De Win, lead cucumber researcher at Proefstation. This research is critical for our growers who frequently ask which spectra is best for their greenhouse and crop variety. Our goal is to act as the bridge between cucumber growers and the latest scientific research, enabling cultivators to enhance their environments and ultimately become more profitable.

Crop-based research results inform unique lighting strategies

LED lighting is a proven, viable option for global crop growers, said David Cohen, CEO of Fluence. Our exploration of the impact of light quality on plant development is driving a deeper conversation about efficacy, yield and quality between growers and their partners. Our commitment to leading cross-geography, multi-crop research will help guide growers in building a supplemental lighting strategy tailored to their unique business goals.

Fluence will distribute research results throughout the year, uncovering how the optimal lighting strategy varies by crop, species and environment. Results from Fluences cucumber trial with Proefstation will be previewed on July 15, 2020 on a webinar hosted by Leo Lansbergen, Fluences horticulture service specialist and expert in cucumber cultivation.

There is no one-size-fits-all approach to determining your lighting strategy, said David Hawley, Ph.D., Fluences senior scientist. Exploring how to manipulate LED technology presents a world of opportunity for us as scientists, but ultimately benefits growers looking to customize their cultivation environments. Insights derived from each study will help growers understand how various spectra impact harvests and plant quality, including factors ranging from nutrition and flavor to shelf life.

For more information about Fluence and its ongoing research initiatives, visit http://www.fluence.science.

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM, creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the worlds top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit http://www.fluence.science.

Link to high resolution pictures: http://www.fluence.science/press-links

View source version on businesswire.com: https://www.businesswire.com/news/home/20200708005470/en/

Contacts

Media Contact: For North America, Emma Chase emma@redfancommunications.com Phone: 512-917-4319

For EMEA, Silvia Nagyova s.nagyova@osram.com Phone: +49 (89) 6213-3939

#distro

Continued here:
Fluence Leads Global Research Initiative to Study Impact of Light Quality on Plant Development, Yield and Crop Quality - Financial Post

Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7…

- Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort led by Dr. Steven Almo at Albert Einstein College of Medicine

- Enhances Cue Biopharmas ability to engineer molecules for therapeutic immune modulation through Immuno-STAT and Neo-STAT platforms

CAMBRIDGE, Mass., July 08, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, today announced the peer-reviewed publication of data focused on generation and evaluation of libraries of checkpoint molecules with directed mutations providing novel biological properties in a paper titled Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex.

In this work, researchers focused primarily on the recently described interaction between B7-1 and PD-L1, two molecules within the B7 superfamily, which are of critical importance for controlling anti-tumor immunity, autoimmunity and infectious diseases. By combining cell microarray and high-throughput FACS methods to screen binding events and map binding interfaces, selective mPD-L1 and mB7-1 mutants with distinct biochemical and functional properties were generated that altered the binding interactions between PD-1 and PD-L1, and CTLA-4 and B7-1 as well as the recently described PD-L1 and B7-1 binding interaction.

Our efforts expand upon the fundamental understanding of critical binding interactions and related downstream signaling cascades by more completely defining the molecular interactions between these key cell surface molecules, said Steven C. Almo, Ph.D., professor and chair of biochemistry, professor of physiology & biophysics and the Wollowick Family Foundation chair in multiple sclerosis and immunology at Albert Einstein College of Medicine, and co-founder of Cue Biopharma. Through these studies we are able to decipher specific molecular and atomic insights to engineer and generate molecules with unique biochemical and functional properties with the aim of developing more efficacious treatments with fewer unwanted side effects.

This approach augments and supplements Cue Biopharmas Immuno-STAT and Neo-STAT platforms, leveraging rational protein engineering to generate therapeutic frameworks possessing desirable drug properties while attenuating and/or abrogating unwanted, deleterious effects. CUE-101, Cue Biopharmas lead asset from the IL-2 based CUE-100 Series, was rationally engineered to enhance the selective activation of the beneficial CD8+ anti-tumor T cells, while abrogating the effects on other immune cell populations that are deleterious to cancer therapy, such as regulatory T cells. A CUE-101 Phase 1 monotherapy trial is ongoing, with enrollment of patients in dose escalation at 13 leading centers in the United States for the treatment of post first-line metastatic and recurrent HPV+ advanced head and neck cancer. Early data metrics from this trial are encouraging with demonstration of safety and tolerability, dose proportional exposure pharmacokinetics (PK) and early, albeit anecdotal, evidence of biologic activity through pharmacodynamics (PD) biomarkers and clinical benefit.

We are highly encouraged by these findings and further research being conducted in Dr. Almos laboratory, which provides us with additional, novel insights into immune receptors, said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. Learnings from this important work will augment and further advance our internal efforts to build out the Immuno-STAT and Neo-STAT platforms and enhance our ability to dial-in/dial-out specific molecular interactions for the therapeutic modulation of the immune system in cancer, autoimmune diseases and chronic infectious diseases.

Albert Einstein College of Medicine and its faculty members acknowledge the following relationships with Cue Biopharma, Inc.: Dr. Almo holds equity in Cue Biopharma, Inc., receives royalties from existing license agreements between Einstein and Cue,and is a member of its Science Advisory Board; Dr.Garrett-Thomson receives royalties; and Albert Einstein College of Medicine holds equity in Cue and receives royalties.

AboutCue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases. The companys proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) is designed to harness the bodys intrinsic immune system without the need for ex vivo manipulation.

Headquartered inCambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visitwww.cuebiopharma.comand follow us on Twitter https://twitter.com/CueBiopharma.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as believe, expect, may, will, should, would, could, seek, intend, plan, goal, project, estimate, anticipate, strategy, future, likely or other comparable terms. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding anticipated results of our drug development efforts, including study results, and our expectations regarding regulatory developments and expected future operating results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, our limited operating history, limited cash and a history of losses; our ability to achieve profitability; potential setbacks in our research and development efforts including negative or inconclusive results from our preclinical studies, our ability to secure requiredU.S. Food and Drug Administration(FDA) or other governmental approvals for our product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on our operations and clinical trials; negative or inconclusive results from our clinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to theFDA; our reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; our ability to obtain adequate financing to fund our business operations in the future; ; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor ContactAshley R. RobinsonLifeSci Advisorsarr@lifesciadvisors.com

Media ContactAlison ChenLifeSci Communicationsachen@lifescicomms.com

Read the original here:
Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7...